Merakris Introduces Dermacyte® AC Matrix Amnion Allograft
01 Oct 2024 //
GLOBENEWSWIRE
Merakris Announces FDA Clearance For Phase II Study Part 2
05 Sep 2024 //
GLOBENEWSWIRE
Jonathan Berlent Joins Merakris as SVP, Head of Strategy and Operations
09 May 2024 //
GLOBENEWSWIRE
Favorable Results From Dermacyte® Matrix Research Study Published
12 Mar 2024 //
GLOBENEWSWIRE
Merakris to Release Final Part 1 Data From Phase 2 Study for Dermacyte® Liquid
20 Feb 2024 //
GLOBENEWSWIRE
Merakris To Share Data from Enrolled First Part of Two-Part Dermacyte Trial
05 Dec 2023 //
GLOBENEWSWIRE
Merakris Announces Nationwide At-Your-Door Autologous Serum Tears Program
12 Oct 2023 //
GLOBENEWSWIRE
Merakris Announces Review in Medical Journal Highlighting Therapeutic Potential
29 Nov 2022 //
GLOBENEWSWIRE
Merakris Sponsored Study Opens Door to Precision-Based Approaches Wound Healing
13 Sep 2022 //
GLOBENEWSWIRE
First Patient Enrolled in Merakris-Sponsored VA Clinical Trial
27 Jul 2022 //
GLOBENEWSWIRE
Merakris CEO To Discuss Dermacyte Development Program
28 Jun 2022 //
GLOBENEWSWIRE